17-N-Allylamino-17-demethoxygeldanamycin

17-N-Allylamino-17-demethoxygeldanamycin is a substance that is being studied in the treatment of cancer, specific young patients with certain types of leukemia or solid tumors, especially kidney tumors. As of June 2005, 17-N-allylamino-17-demethoxygeldanamycin is undergoing Phase 1 and Phase 2 clinical trials. It belongs to the family of drugs called antitumor antibiotics.